Drug Most Volatile Stocks: Zogenix, (NASDAQ:ZGNX), Ventrus Biosciences (NASDAQ:VTUS), NanoViricides (NYSEMKT:NNVC), Tonix Pharmaceuticals Holding (NASDAQ:TNXP), ITI (NASDAQ:ITCI)

Stock analysts at R. F. Lafferty initiated coverage on shares of Zogenix (NASDAQ:ZGNX) in a report issued on Friday. The firm set a “buy” rating and a $3.50 price target on the stock. R. F. Lafferty’s target price suggests a potential upside of 90.22% from the company’s current price. Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is 17.58%. On last trading day company shares ended up $1.94. Analysts mean target price for the company is $4.48. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is -13.61%.

Ventrus Biosciences, Inc. (NASDAQ:VTUS) on 9 June announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) in connection with the upcoming annual meeting of Ventrus stockholders. The Company also announced that it is commencing the mailing of the definitive proxy materials to its stockholders. The annual meeting of stockholders of Ventrus Biosciences will be held at 10:00 a.m. Eastern Time on July 10th, 2014, at Ventrus headquarters located at 99 Hudson Street, 5th Floor, New York, New York. Ventrus Biosciences Inc. (NASDAQ:VTUS) shares advanced 2.19% in last trading session and ended the day on $1.40. VTUS return on assets is -67.60%.Ventrus Biosciences Inc. (NASDAQ:VTUS) quarterly performance is 0.72%.

NanoViricides, Inc. (NYSEMKT:NNVC) reports that its President, Dr. Anil Diwan, presented at the Wall Street Analyst Forum’s 25th Annual Institutional Investor Conference on 19 June. NanoViricides Inc. (NYSEMKT:NNVC) shares moved up 8.06% in last trading session and was closed at $4.69, while trading in range of $4.30 – $4.69. NanoViricides Inc. (NYSEMKT:NNVC) year to date (YTD) performance is -2.29%.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to develop TNX-102 SL, a proprietary sublingual formulation of cyclobenzaprine HCl, for the treatment of post-traumatic stress disorder (PTSD). Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ended the last trading day at $12.42. Company weekly volatility is calculated as 5.20% and price to cash ratio as 2.48.Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) showed a positive weekly performance of 11.89%.

ITI Inc. (NASDAQ:ITCI) VP Lawrence P. Wennogle sold 6,000 shares of ITI stock on the open market in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $15.00, for a total transaction of $90,000.00. Following the completion of the transaction, the vice president now directly owns 106,500 shares of the company’s stock, valued at approximately $1,597,500. ITI Inc. (NASDAQ:ITCI) weekly performance is 14.03%. On last trading day company shares ended up $19.26. Analysts mean target price for the company is $29.67. ITI Inc. (NASDAQ:ITCI) distance from 50-day simple moving average (SMA50) is 19.01%.